within Pharmacolibrary.Drugs.ATC.R;

model R07AX30
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.0002883333333333333,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0947,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 60
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R07AX30</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ivacaftor and lumacaftor is a fixed-dose combination medication used to treat cystic fibrosis in patients with homozygous F508del mutation in the CFTR gene. Ivacaftor acts as a CFTR potentiator, while lumacaftor functions as a CFTR corrector. The combination is approved for use and marketed under the trade name Orkambi.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult patients with cystic fibrosis, after repeated oral dosing of lumacaftor/ivacaftor combination (400 mg/250 mg) every 12 hours under fed conditions.</p><h4>References</h4><ol><li><p> (2016). Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. <i>The Medical letter on drugs and therapeutics</i> 58(1491) 41–42. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27027688/\">https://pubmed.ncbi.nlm.nih.gov/27027688</a></p></li><li><p>van Koningsbruggen-Rietschel, S, et al., &amp; Van de Steen, O (2020). GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). <i>Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society</i> 19(2) 292–298. DOI:<a href=\"https://doi.org/10.1016/j.jcf.2019.09.006\">10.1016/j.jcf.2019.09.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31594690/\">https://pubmed.ncbi.nlm.nih.gov/31594690</a></p></li><li><p> (2018). Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis. <i>The Medical letter on drugs and therapeutics</i> 60(1558) 174–176. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30335045/\">https://pubmed.ncbi.nlm.nih.gov/30335045</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R07AX30;
